Can a Triple-Drug cocktail tame resistant myeloma?
NCT ID NCT04790474
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This trial is testing whether a combination of three drugs—ixazomib, pomalidomide, and dexamethasone—can help people with multiple myeloma that has relapsed or become resistant after prior treatments like daratumumab, lenalidomide, and bortezomib. The study will measure how long patients live without the disease progressing, as well as overall survival and response rates. Participants will receive the drug combo in cycles, with adjustments for side effects, and may continue for up to 24 months or until the disease worsens.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of three drugs: ixazomib, pomalidomide, and dexamethasone
- What this could lead to
- If successful, this could offer a new treatment option for people with multiple myeloma that has returned after standard therapies, potentially extending the time before the disease progresses.
- What could go wrong
- This is a phase 2 trial with a modest number of participants, so results may not be definitive. The drugs can cause side effects like low blood counts, fatigue, and increased infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emek Medical Center
Afula, 18101, Israel
-
Hadassah Ein-Kerem Medical Center
Jerusalem, Israel
-
Rabin Medical Center
Petah Tikva, Israel
-
Rambam Medical Center
Haifa, Israel
-
Shearei Zedek Medical Center
Jerusalem, Israel
-
Sheba Tel Hashomer
Ramat Gan, Israel
-
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a single gene therapy turn the body into a Cancer-Fighting factory?
- Can a One-Two drug punch beat back Hard-to-Treat myeloma?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Engineered immune cells take on incurable blood cancer
- Double-barreled CAR t therapy takes aim at hard-to-treat myeloma